文献速递眼底病与葡萄膜炎

基于AI的OCT评估抗VEGF负荷期治疗nAMD的解剖学应答

AI-Based OCT Assessment of Anatomic Response During the Loading Phase of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

这项多中心回顾性队列研究纳入224只初治nAMD眼,比较贝伐珠单抗、阿柏西普2mg与法瑞西单抗负荷期后的功能和解剖结局。AI分割OCT显示三组均改善,法瑞西单抗和阿柏西普的干黄斑率高于贝伐珠单抗,BCVA组间无显著差异。

要点

  • 法瑞西单抗干黄斑率80.3%、阿柏西普67.9%,均高于贝伐珠单抗41.3%(P<0.001)。
  • 三组BCVA在12周均改善,但基线校正后组间无显著差异。
  • 探索性复合OCT指标ΔCOMBO的AUC为0.959(95%CI 0.907-0.999)。

核心结论

  • 三种抗VEGF药物治疗初治nAMD负荷期后均改善功能和解剖结局,基线校正分析显示解剖应答模式存在组间差异。

研究设计与样本

  • 多中心回顾性队列研究,纳入224只初治nAMD眼,分别接受贝伐珠单抗(n=80)、阿柏西普2mg(n=78)或法瑞西单抗(n=66)三次每月注射。

主要发现

  • 组内分析显示第12周BCVA和OCT参数均改善,贝伐珠单抗和法瑞西单抗组BCVA改善有统计学意义。
  • 基线校正分析中OCT结局出现组间差异,而BCVA无显著组间差异。
  • 法瑞西单抗组干黄斑率80.3%、阿柏西普2mg组67.9%,均高于贝伐珠单抗组41.3%(P<0.001)。
  • 探索性复合指标ΔCOMBO展现出高判别性能,AUC=0.959(95%CI 0.907-0.999)。

关键数值与推荐

  • 主要结局为定性干黄斑,即无视网膜内液和视网膜下液。
  • ΔCOMBO定义为IRFv与SRFv中百分比较小的那个降低幅度,采用ROC分析评估。

临床怎么用

  • AI辅助OCT分割可量化IRFv、SRFv和色素上皮脱离体积,有助于评估负荷期解剖应答。
  • 探索性ΔCOMBO指标可能帮助刻画短期解剖应答,但需外部验证后方可用于临床决策。

局限性

  • 研究为回顾性设计,探索性AI生物标志物需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare functional and anatomic outcomes after the loading phase of intravitreal bevacizumab, aflibercept 2 mg, or faricimab in treatment-naive neovascular age-related macular degeneration (nAMD), using artificial intelligence (AI)-based optical coherence tomography (OCT) analysis. METHODS: This multicenter retrospective cohort study included 224 eyes. Patients received three monthly injections of bevacizumab (n = 80), aflibercept 2 mg (n = 78), or faricimab (n = 66). Best-corrected visual acuity (BCVA) and spectral-domain OCT were assessed at baseline and week 12. AI-based segmentation quantified volumetric measurements of intraretinal fluid (IRFv), subretinal fluid (SRFv), and pigment epithelial detachment. The primary outcome was qualitative dry macula (absence of intraretinal fluid and subretinal fluid). An exploratory composite OCT biomarker (ΔCOMBO), defined as the lesser percentage reduction between IRFv and SRFv, was evaluated as a hypothesis-generating metric using receiver operating characteristic analysis. Baseline-adjusted analyses and multivariable logistic regression were performed. RESULTS: Descriptive within-group analyses showed improvement in BCVA and reduction in OCT parameters at week 12 in treatment groups. BCVA improvement was statistically significant in the bevacizumab and faricimab groups. In baseline-adjusted analyses, between-group differences emerged for OCT outcomes, whereas no significant between-group differences were observed for BCVA. Higher rates of dry macula were observed with faricimab (80.3%) and aflibercept 2 mg (67.9%) compared with bevacizumab (41.3%) (P < 0.001). The exploratory composite metric ΔCOMBO showed high discriminative performance (area under the curve = 0.959; 95% confidence interval, 0.907-0.999). CONCLUSIONS: All agents improved functional and anatomic outcomes after the loading phase in treatment-naive nAMD. Baseline-adjusted analyses showed differences in anatomic response patterns across treatments. Exploratory AI-based OCT biomarkers may help characterize short-term anatomic response; however, these findings require external validation.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Nassisi M, Eandi CM, Donà C, et al. AI-Based OCT Assessment of Anatomic Response During the Loading Phase of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2026. PMID: 42929689. doi:10.1167/iovs.67.12.62

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。